• Je něco špatně v tomto záznamu ?

Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients

N. Petejova, A. Martinek, J. Zahalkova, J. Duricova, H. Brozmannova, K. Urbanek, M. Grundmann, J. Plasek, I. Kacirova

. 2014 ; 158 (1) : 65-72. [pub] 20121106

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15026709

AIMS: To assess the influence of continuous venovenous hemofiltration (CVVH) at a filtration rate of 45 mL/kg/h on vancomycin pharmacokinetics in critically ill septic patients with acute kidney injury (AKI). METHODS: Seventeen adult septic patients with acute kidney injury treated with CVVH and vancomycin were included. All patients received first dose of 1.0 g intravenously followed by 1.0 g/12 h if not adjusted. In sixteen patients vancomycin was introduced on the day of the start of CRRT therapy. Blood samples and ultrafiltrates were obtained before and 0.5, 1, 6 and 12 h after vancomycin administration. RESULTS: On the first day, the median total vancomycin clearance (Cltot) was 0.89 mL/min/kg (range 0.31 - 2.16). CRRT clearance accounted for around 50-60% of the total clearance of vancomycin found in a population with normal renal function (0.97 mL/min/kg). Vancomycin serum concentrations after the first dose were below the required target of 10 mg/L as early as 6 h in 10 patients, AUC0-24/MIC ≥ 400 ratio was achieved in 10 patients on the first day. CONCLUSIONS: CVVH at a filtration rate of 45 mL/kg/h leads to high and rapid extracorporeal removal of vancomycin in critically ill patients. Due to the rapid change in patient clinical status it was impossible to predict a fixed dosage regimen. We recommend blood sampling as early as 6 h after first vancomycin dose with maintenance dose based on vancomycin serum level monitoring.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15026709
003      
CZ-PrNML
005      
20150818085839.0
007      
ta
008      
150811s2014 xr f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2012.092 $2 doi
035    __
$a (PubMed)23132513
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Petejová, Naděžda $u Department of Internal Medicine, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Czech Republic $7 xx0143726
245    10
$a Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients / $c N. Petejova, A. Martinek, J. Zahalkova, J. Duricova, H. Brozmannova, K. Urbanek, M. Grundmann, J. Plasek, I. Kacirova
520    9_
$a AIMS: To assess the influence of continuous venovenous hemofiltration (CVVH) at a filtration rate of 45 mL/kg/h on vancomycin pharmacokinetics in critically ill septic patients with acute kidney injury (AKI). METHODS: Seventeen adult septic patients with acute kidney injury treated with CVVH and vancomycin were included. All patients received first dose of 1.0 g intravenously followed by 1.0 g/12 h if not adjusted. In sixteen patients vancomycin was introduced on the day of the start of CRRT therapy. Blood samples and ultrafiltrates were obtained before and 0.5, 1, 6 and 12 h after vancomycin administration. RESULTS: On the first day, the median total vancomycin clearance (Cltot) was 0.89 mL/min/kg (range 0.31 - 2.16). CRRT clearance accounted for around 50-60% of the total clearance of vancomycin found in a population with normal renal function (0.97 mL/min/kg). Vancomycin serum concentrations after the first dose were below the required target of 10 mg/L as early as 6 h in 10 patients, AUC0-24/MIC ≥ 400 ratio was achieved in 10 patients on the first day. CONCLUSIONS: CVVH at a filtration rate of 45 mL/kg/h leads to high and rapid extracorporeal removal of vancomycin in critically ill patients. Due to the rapid change in patient clinical status it was impossible to predict a fixed dosage regimen. We recommend blood sampling as early as 6 h after first vancomycin dose with maintenance dose based on vancomycin serum level monitoring.
650    _2
$a akutní poškození ledvin $x krev $x terapie $7 D058186
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antibakteriální látky $x krev $x farmakokinetika $7 D000900
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a kritický stav $7 D016638
650    _2
$a monitorování léčiv $7 D016903
650    _2
$a ženské pohlaví $7 D005260
650    12
$a hemofiltrace $7 D006440
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a sepse $x krev $x farmakoterapie $7 D018805
650    _2
$a vankomycin $x krev $x farmakokinetika $7 D014640
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Martínek, Arnošt, $d 1952- $7 nlk20020123459 $u Department of Internal Medicine, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Czech Republic
700    1_
$a Zahálková, Jana $7 xx0109308 $u Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc; Stredomoravska nemocnicni, Hospital Sternberk
700    1_
$a Ďuricová, Jana $7 xx0094983 $u Department of Clinical Pharmacology, Faculty of Medicine and University Hospital Ostrava
700    1_
$a Brozmannová, Hana $7 _AN083837 $u Department of Clinical Pharmacology, Faculty of Medicine and University Hospital Ostrava
700    1_
$a Urbánek, Karel, $d 1969- $7 xx0078289 $u Department of Clinical Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc
700    1_
$a Grundmann, Milan, $d 1939- $7 nlk20010093222 $u Department of Clinical Pharmacology, Faculty of Medicine and University Hospital Ostrava
700    1_
$a Plášek, Jiří $7 xx0107483 $u Department of Internal Medicine, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Czech Republic
700    1_
$a Kacířová, Ivana $7 xx0081201 $u Department of Clinical Pharmacology, Faculty of Medicine and University Hospital Ostrava
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic $x 1213-8118 $g Roč. 158, č. 1 (2014), s. 65-72
856    41
$u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20150811 $b ABA008
991    __
$a 20150817095629 $b ABA008
999    __
$a ok $b bmc $g 1087919 $s 909745
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 158 $c 1 $d 65-72 $e 20121106 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20150811

Najít záznam

Citační ukazatele

Možnosti archivace